Listed
2016-11
First close
USD 365.39
split-adjusted
Since listing
+148%
23 points
Current
USD 904.35
— · 2026-11-08 04:51 ET
Peak
USD 973.36
—2026-11
Low
USD 739.57
—2026-10
Latest change
+0.2%
2026-11-05 → 2026-11-06
Change since first
+21.9%
2026-10
52-week range
USD 591.52 – USD 991.73
Drawdown
-8.8%
Avg vol 3m
774K
Price history
2026–2026Monthly closes from Yahoo Finance, split-adjusted, dividends excluded. Earlier points are actual closes, not reconstructed.
DateCloseChange
- 11-06USD 904.35+0.2%
- 11-05USD 902.90-3.0%
- 11-04USD 930.67-4.4%
- 11-03USD 973.36+1.3%
- 11-02USD 961.26+3.6%
- 10-30USD 927.89+13.3%
- 10-29USD 818.77+0.7%
- 10-28USD 813.27-0.3%
- 10-27USD 816.10+1.0%
- 10-26USD 807.67+0.3%
- 10-23USD 805.02-1.7%
- 10-22USD 819.09+1.7%
- 10-21USD 805.67-0.2%
- 10-20USD 807.48+3.3%
- 10-19USD 782.04-1.1%
- 10-16USD 790.74-0.7%
- 10-15USD 796.34+2.3%
- 10-14USD 778.36+3.4%
- 10-13USD 753.12-1.3%
- 10-12USD 762.81+2.2%
- 10-09USD 746.54+0.9%
- 10-08USD 739.57-0.3%
- 10-07USD 742.12—
Ownership & Control
Latest available filings- Controlling entity
- Publicly held — no controlling shareholder disclosed
- Insiders
- —
- Institutions
- —
- Free float
- —
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →- Regeneron Reports Third Quarter 2026 Financial and Operating Results with Revenues Up 36% to $5.1 Billion and Expanded Sanofi Alliance2026-10-30
- Regeneron Pharmaceuticals Files Q3 2026 Form 10-Q Showing Total Assets Reaching $44.41 Billion and Full Repayment of Sanofi Development Balance2026-10-22
- Regeneron Details 2026 Annual Meeting Votes, Board Declassification, and 2025 Capital Allocation in Definitive Proxy Statement2026-04-24